Jeffrey D. Kent
- Genetics top 0.2%
- Epidemiology top 0.5%
- Pharmacology top 0.2%
- Surgery top 2%
- Immunology top 2%
- Co-authors
- William J. SandbornRemo PanaccionePaul RutgeertsJu LiPaul F. PollackKenneth M. VerburgStefan SchreiberAndrew Whelton
- Topics
- Inflammatory mediators and NSAID effects (17 papers)Inflammatory Bowel Disease (14 papers)Microscopic Colitis (11 papers)
- Cited by
- PharmacologyGeneticsEpidemiology
- Partner nations
- United StatesGermanyFrance
In The Last Decade
Jeffrey D. Kent
60 papers receiving 6.9k citations
Hit Papers
Peers
Comparison fields: 5 of 135
- Genetics 3.6k
- Epidemiology 2.8k
- Pharmacology 2.3k
- Surgery 1.8k
- Immunology 996
Countries citing papers authored by Jeffrey D. Kent
This map shows the geographic impact of Jeffrey D. Kent's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeffrey D. Kent with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeffrey D. Kent more than expected).
Fields of papers citing papers by Jeffrey D. Kent
This network shows the impact of papers produced by Jeffrey D. Kent. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeffrey D. Kent. The network helps show where Jeffrey D. Kent may publish in the future.
Co-authorship network of co-authors of Jeffrey D. Kent
This figure shows the co-authorship network connecting the top 25 collaborators of Jeffrey D. Kent. A scholar is included among the top collaborators of Jeffrey D. Kent based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeffrey D. Kent. Jeffrey D. Kent is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 8 | |
| 2 | 9 | |
| 3 | Adalimumab Induction Therapy for Crohn Disease Previously Treated with Infliximab | 10 |
| 4 | 13 | |
| 5 | 28 | |
| 6 | 12 | |
| 7 | 12 | |
| 8 | 8 | |
| 9 | 254 | |
| 10 | Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trialbreakdown → | 798 |
| 11 | 19 | |
| 12 | 3 | |
| 13 | Adalimumab for Maintenance of Clinical Response and Remission in Patients With Crohn’s Disease: The CHARM Trialbreakdown → | 1655 |
| 14 | 32 | |
| 15 | 39 | |
| 16 | 88 | |
| 17 | Gastrointestinal Toxicity With Celecoxib vs Nonsteroidal Anti-inflammatory Drugs for Osteoarthritis and Rheumatoid Arthritisbreakdown → | 2401 |
| 18 | 15 | |
| 19 | 35 | |
| 20 | 64 |
About Jeffrey D. Kent
Jeffrey D. Kent is a scholar working on Pharmacology, Nephrology and Hepatology, having authored 60 papers that have together received 7.2k indexed citations. Recurring topics across this work include Inflammatory mediators and NSAID effects (17 papers), Inflammatory Bowel Disease (14 papers) and Microscopic Colitis (11 papers). The work is most often cited by research in Pharmacology (2.3k citations), Genetics (3.6k citations) and Epidemiology (2.8k citations). Jeffrey D. Kent has collaborated with scholars based in United States, Germany and France. Frequent co-authors include William J. Sandborn, Remo Panaccione, Paul Rutgeerts, Ju Li, Paul F. Pollack, Kenneth M. Verburg, Stefan Schreiber, Andrew Whelton, J B Lefkowith and Jay L. Goldstein. Their work appears in journals such as JAMA, Journal of Biological Chemistry and Annals of Internal Medicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.